Clinical trials: Renal Neoplasms
Cardiac Disease, Cancer
Electronic Medical Records and Genomics (eMERGE) Phase III
The Electronic Medical Records and Genomics (eMERGE) Network is in its third phase and during this time is enrolling and sequencing 25,000 individuals on a custom sequencing panel of clinically relevant, actionable genes.
- Conditions
- Cardiac Disease, Cancer, Hypercholesterolemia, Diabetes
- Trial name
- eMERGE (NCT03394859)
- Volunteers
- 25,380 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Renal Cell Carcinoma
A Companion Diagnostic Study to Develop Circulating Exosomes as Predictive Biomarkers for the Response to Immunotherapy in Renal Cell Carcinoma
Immune checkpoint inhibitors targeting PD-1 or PD-L1 have been developed and clinical trials showning better response in unselected patients with metastatic renal cell carcinoma (RCC).
- Trial name
- NCT05705583
- Testing
- Other: Blood and Urine Collection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Renal Neoplasm, Renal Injury
The Effect of Remote Ischemic Preconditioning on Kidney Function in Patients Undergoing Partial Nephrectomy
This study is intended to evaluate the renal protective effect of Remote Ischemic Preconditioning (RIPC) in patients undergoing partial nephrectomy.
- Trial name
- NCT03273751
- Testing
- Remote Ischemic Preconditioning
- Where
- South Korea
- Volunteers
- 86 people
- Sponsor
- Seoul National University Hospital
Renal Cell Carcinoma
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
This study will assess whether DNA released by kidney cancer into the blood stream and urine of patients can be used to monitor tumor burden and tumor response to treatment in patients receiving immunotherapy
- Trial name
- NCT04883827
- Testing
- Blood collection, Urine collection
- Where
- 3 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Carcinoma, Renal Cell
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who…
- Trial name
- NCT00073307
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 121 sites in United States, Argentina and 17 more
- Volunteers
- 903 people
- Sponsor
- Bayer
Melanoma, Renal Cell Carcinoma (RCC)
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
This study aims to develop methods for quantitative imaging of solid tumors in patients who are receiving immunotherapies that have a delayed mechanism of action.
- Conditions
- Melanoma, Renal Cell Carcinoma (RCC), Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01666353
- Testing
- PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Renal Cell Carcinoma
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Girentuximab is an antibody against Carbonic Anhydrase IX (CAIX), an antigen that is expressed on the cell surface of 95% of clear cell RCC (ccRCC).
- Trial name
- NCT02883153
- Testing
- Zirconium-89 girentuximab PET/CT
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Neoplasms (Cancer / Tumors), Colorectal Neoplasms
A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment
Many clinical trials evaluating cancer treatments require patients to undergo testing for specific molecular markers as part of eligibility screening, typically using immunohistochemistry or sequencing.
- Conditions
- Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms
- Trial name
- FATHOM (NCT07814872)
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- Harvard Medical School (HMS and HSDM)
Pediatric Disorder, Hydronephrosis in Children
Effect of Concomitant Bladder Neck Incision and Urethral Valve Ablation on Surgical Re-intervention Rate for Patients With Posterior Urethral Valve
To determine the short-term effects of concurrent valve ablation and bladder neck incision on re-intervention rate for patients with posterior urethral valve.
- Conditions
- Pediatric Disorder, Hydronephrosis in Children, Hydronephrosis, Secondary, Hydronephrosis Congenital
- Trial name
- NCT05087537
- Testing
- Valve ablation, Valve ablation and bladder neck incision
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Mansoura University
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT05896839
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 26 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one…
- Trial name
- NCT04865939
- Testing
- sterile water irrigation, Gemcitabine
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- University of Texas Southwestern Medical Center
Kidney Cancer
High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill renal cell carcinoma (kidney cancer) cells. PURPOSE: This phase II trial is studying how well high-dose intravenous interleukin-2 works in treating…
- Trial name
- NCT00080977
- Testing
- aldesleukin
- Where
- United States
- Sponsor
- Blumenthal Cancer Center at Carolinas Medical Center
Advanced Solid Tumor, Gynecologic Cancer
A Study of PY314 in Subjects With Advanced Solid Tumors
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including…
- Conditions
- Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer
- Trial name
- NCT04691375
- Testing
- PY314, Combination Therapy: PY314 + Pembrolizumab
- Where
- 23 sites in United States
- Volunteers
- 86 people
- Sponsor
- Ikena Oncology
Clear Cell Renal Cell Carcinoma
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
This is a prospective, single-center, single-arm, diagnostic phase 2 study in patients who have renal masses scheduled for surgical resection.
- Trial name
- NCT07101900
- Testing
- 68Ga-NYM096 PET/CT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Renal Cancer
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be applied in clinical practice as…
- Trial name
- KIDNEY-PAGER (NCT06145139)
- Where
- Denmark
- Volunteers
- 500 people
- Sponsor
- University of Aarhus
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Lymphoma, Sarcoma
A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas
Background: Vorinostat and bortezomib are anti-tumor drugs that have been approved by the Food and Drug Administration to treat different kinds of myeloma and lymphoma in adults.
- Conditions
- Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
- Trial name
- NCT01132911
- Testing
- Vorinostat (SAHA), Velcade (PS-341, Bortezomib)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Chemotherapeutic Toxicity
Role of Renal Biopsy in the Suspicion of Nephrotoxicity of Immunotherapy (Checkpoint Inhibitors) in Solid Cancer
Checkpoint inhibitors represent a new class of widely used immunotherapy, however with immune-mediated adverse effects, with renal damage estimated at 1.4% and 4.9% depending on the series.
- Trial name
- NEPHROTOX (NCT06357871)
- Testing
- No intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Central Hospital, Nancy, France
Advanced Malignancy, Advanced Solid Tumors
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Neoplasm, Metastasis
- Trial name
- SDX-0101 (NCT02743637)
- Testing
- SDX-7320
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- SynDevRx, Inc.